PDCD1 and Sepsis: In preclinical models, blocking PD-1 or PD-L1 with monoclonal antibodies has been shown to reverse T-cell exhaustion and enhance pathogen clearance, offering a promising therapeutic strategy for the immunosuppressive phase of sepsis [22].